Evidence map›Paper›PMID 40599274›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Icariside Ⅱ Inhibits Hepatitis B Virus and Modulates Mitochondrial Fission

Zhengyun Liu, Juan Wen, Guoli Chen, Wan Yu, Guo Luo, Qihai Gong, Huan Wang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhengyun Liu（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.
Juan Wen（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.
Guoli Chen（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.
Wan Yu（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.
Guo Luo（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.
Qihai Gong（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.
Huan Wang（ 563000） Key Laboratory of Infectious Disease & Biosafety, Zunyi Medical University, Zunyi 563000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the Methods: HBV-positive hepatocellular carcinoma HepAD38 cells were used as the cellular model. The cytotoxicity of ICS Ⅱ was assessed via CCK8 assay. The secretion levels of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg), as well as HBV DNA copy numbers, were measured by ELISA and qPCR after treatment with ICS Ⅱ alone or ICS Ⅱ in combination with entecavir (ENT). The effects of ICS Ⅱ on mitochondrial morphology and motility were observed using confocal laser scanning microscopy and transmission electron microscopy (TEM). After ICS Ⅱ treatment, Western blot was performed to analyze the expression levels of key proteins involved in mitochondrial dynamics. Additionally, intracellular reactive oxygen species (ROS) production was evaluated via fluorescence staining. Results: The CCK8 assay results showed that ICS Ⅱ treatment at 25 μmol/L had no significant effect on cell proliferation after 72 h. ICS Ⅱ significantly inhibited the secretion levels of HBsAg and HBeAg, with the respective inhibition rates reaching 54.90% and 39.65% ( Conclusion: ICS Ⅱ inhibits HBV replication in HepAD38 cells, and the underlying mechanism may be associated with the promotion of mitochondrial fission and suppression of ROS production.

Indexed as

Antiviral AgentsHepatitis B virusMitochondrial DynamicsCell Line, TumorHepatitis B e AntigensHepatitis B Surface AntigensHumansMitochondriaReactive Oxygen SpeciesAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensReactive Oxygen SpeciesEpimedium herbHepatitis B virusMitochondria

Identifiers

PMID40599274
PMCPMC12207037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.